Cardio Diagnostics Engages IBN to Support Communications Strategy for Cardiovascular Solutions

Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO), a precision cardiovascular medicine company that leverages epigenetics, genetics and artificial intelligence, has engaged IBN to support its corporate communications strategy. This partnership comes as the company advances blood-based solutions for the prevention and detection of cardiovascular disease, which remains a leading cause of mortality worldwide. The collaboration aims to amplify the company's message about its innovative approach to cardiovascular care through enhanced communication channels.

The company develops and commercializes clinical tests and data platforms that integrate molecular biomarkers with AI to generate patient-specific insights. Their product portfolio includes Epi+Gen CHD(TM), a prescription-only test for assessing three-year coronary heart disease risk, PrecisionCHD(TM) for detection and management, HeartRisk(TM) for population-level intelligence and CardioInnovate360(TM) to support cardiovascular therapy development. These technologies represent a shift toward more personalized and precise cardiovascular medicine that could potentially transform how heart disease is prevented and managed.

IBN, through its BioMedWire platform, provides specialized communications services focused on the biotechnology, biomedical sciences and life sciences sectors. As part of the Dynamic Brand Portfolio@IBN, BioMedWire offers access to wire solutions, article and editorial syndication to over 5,000 outlets, enhanced press release services, social media distribution, and tailored corporate communications solutions. The platform's broad reach and specialized focus make it particularly suited for companies like Cardio Diagnostics that operate in the complex medical technology space.

The engagement with IBN comes at a critical time for Cardio Diagnostics as it seeks to increase awareness of its AI-driven Integrated Genetic-Epigenetic Engine, which the company calls its "Core Technology." This technology underpins their approach to making cardiovascular disease prevention, detection, and management more accessible, personalized, and precise. By partnering with a specialized communications firm, Cardio Diagnostics aims to effectively communicate the scientific and clinical significance of their work to investors, healthcare professionals, and the broader public.

Cardio Diagnostics was formed to further develop and commercialize clinical tests using their proprietary AI-driven technology with the goal of becoming a leading medical technology company for improving prevention, detection, and treatment of cardiovascular disease. The company's news and updates are available through their newsroom at https://ibn.fm/CDIO. This strategic communications partnership represents an important step in the company's growth trajectory as it works to establish itself in the competitive precision medicine landscape.